The first breakthrough was the advent of gene-splicing technology and the production of a recombinant hepatitis B virus ... with the decreasing ability of antibodies to confer protective immunity.

with nearly all subjects developing hepatitis A antibodies (anti-HAV) within 2 weeks. [3] However, a second dose of vaccine, given 6 or 12 to 18 months after the first dose in accordance with the ...

With an ever increasing number of patients being treated with IVIg for a wide array of immune-mediated disease, it is important that passive antibody transfer is considered when unexpected ...

Preterm babies who receive a hepatitis B virus (HBV) vaccine at birth aren't at increased risk of developing a chronic lung disease that affects newborns, according to a new study.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Bluejay Therapeutics’ fully human immunoglobulin G1 (IgG1) monoclonal antibody, brelovitug, to treat chronic ...

What our study showed was that during a chronic hepatitis C infection, antibodies on the virus surface form an antibody cluster that persistently stimulates the B cells to mutate," explains lead ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).